scholarly journals Adipose Tissue Inflammation and Metabolic Disorders

Author(s):  
Felipe Henriques ◽  
Alexander H. Bedard ◽  
Miguel Luiz Batista Júnior
Aging ◽  
2019 ◽  
Vol 11 (23) ◽  
pp. 11084-11110 ◽  
Author(s):  
Dan Li ◽  
Qianyu Liu ◽  
Xiuqiang Lu ◽  
Zhengqiu Li ◽  
Chunming Wang ◽  
...  

Metabolism ◽  
2013 ◽  
Vol 62 (11) ◽  
pp. 1673-1685 ◽  
Author(s):  
Viswanathan Saraswathi ◽  
Christopher J. Ramnanan ◽  
Anson W. Wilks ◽  
Cyrus V. Desouza ◽  
Amy A. Eller ◽  
...  

Obesity ◽  
2015 ◽  
Vol 23 (11) ◽  
pp. 2199-2206 ◽  
Author(s):  
Chun-Pyo Hong ◽  
Chang Ho Yun ◽  
Gil-Woo Lee ◽  
Areum Park ◽  
You-Me Kim ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Jolanda H. M. van Bilsen ◽  
Willem van den Brink ◽  
Anita M. van den Hoek ◽  
Remon Dulos ◽  
Martien P. M. Caspers ◽  
...  

Metabolic disorders, such as obesity and type 2 diabetes have a large impact on global health, especially in industrialized countries. Tissue-specific chronic low-grade inflammation is a key contributor to complications in metabolic disorders. To support therapeutic approaches to these complications, it is crucial to gain a deeper understanding of the inflammatory dynamics and to monitor them on the individual level. To this end, blood-based biomarkers reflecting the tissue-specific inflammatory dynamics would be of great value. Here, we describe an in silico approach to select candidate biomarkers for tissue-specific inflammation by using a priori mechanistic knowledge from pathways and tissue-derived molecules. The workflow resulted in a list of candidate markers, in part consisting of literature confirmed biomarkers as well as a set of novel, more innovative biomarkers that reflect inflammation in the liver and adipose tissue. The first step of biomarker verification was on murine tissue gene-level by inducing hepatic inflammation and adipose tissue inflammation through a high-fat diet. Our data showed that in silico predicted hepatic markers had a strong correlation to hepatic inflammation in the absence of a relation to adipose tissue inflammation, while others had a strong correlation to adipose tissue inflammation in the absence of a relation to liver inflammation. Secondly, we evaluated the human translational value by performing a curation step in the literature using studies that describe the regulation of the markers in human, which identified 9 hepatic (such as Serum Amyloid A, Haptoglobin, and Interleukin 18 Binding Protein) and 2 adipose (Resistin and MMP-9) inflammatory biomarkers at the highest level of confirmation. Here, we identified and pre-clinically verified a set of in silico predicted biomarkers for liver and adipose tissue inflammation which can be of great value to study future development of therapeutic/lifestyle interventions to combat metabolic inflammatory complications.


2020 ◽  
Vol 134 (12) ◽  
pp. 1403-1432 ◽  
Author(s):  
Manal Muin Fardoun ◽  
Dina Maaliki ◽  
Nabil Halabi ◽  
Rabah Iratni ◽  
Alessandra Bitto ◽  
...  

Abstract Flavonoids are polyphenolic compounds naturally occurring in fruits and vegetables, in addition to beverages such as tea and coffee. Flavonoids are emerging as potent therapeutic agents for cardiovascular as well as metabolic diseases. Several studies corroborated an inverse relationship between flavonoid consumption and cardiovascular disease (CVD) or adipose tissue inflammation (ATI). Flavonoids exert their anti-atherogenic effects by increasing nitric oxide (NO), reducing reactive oxygen species (ROS), and decreasing pro-inflammatory cytokines. In addition, flavonoids alleviate ATI by decreasing triglyceride and cholesterol levels, as well as by attenuating inflammatory mediators. Furthermore, flavonoids inhibit synthesis of fatty acids and promote their oxidation. In this review, we discuss the effect of the main classes of flavonoids, namely flavones, flavonols, flavanols, flavanones, anthocyanins, and isoflavones, on atherosclerosis and ATI. In addition, we dissect the underlying molecular and cellular mechanisms of action for these flavonoids. We conclude by supporting the potential benefit for flavonoids in the management or treatment of CVD; yet, we call for more robust clinical studies for safety and pharmacokinetic values.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1212-P ◽  
Author(s):  
JURAJ KOSKA ◽  
TRACY OSREDKAR ◽  
D'SOUZA KAREN ◽  
SANDEEP SINHA ◽  
CHRISTIAN MEYER ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 39-OR
Author(s):  
ERIC LONTCHI-YIMAGOU ◽  
SONA KANG ◽  
KEHAO ZHANG ◽  
AKANKASHA GOYAL ◽  
JEE YOUNG YOU ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2032-P
Author(s):  
ANA E. ESPINOSA DE YCAZA ◽  
ESBEN SØNDERGAARD ◽  
MARIA MORGAN-BATHKE ◽  
DANAE A. DELIVANIS ◽  
BARBARA G. CARRANZA LEON ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document